ClinicalTrials.Veeva

Menu

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Stanford University logo

Stanford University

Status

Completed

Conditions

Lymphomas: Non-Hodgkin Marginal Zone
Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
Lymphomas: Non-Hodgkin Cutaneous Lymphoma
Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Lymphomas: Non-Hodgkin Diffuse Large B-Cell
Lymphomas: Non-Hodgkin
Lymphoma, Non-Hodgkin
Lymphomas: Non-Hodgkin Peripheral T-Cell
Lymphomas: Non-Hodgkin Mantle Cell

Treatments

Drug: Rituximab
Drug: Epratuzumab

Study type

Interventional

Funder types

Other
Industry
NIH

Identifiers

NCT00398372
77550
LYMNHL0031
CA09287
200114861
NCT00398372
CA111827

Details and patient eligibility

About

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems